RxDoctor Payments Data

Sarah Buenviaje

Nurse Practitioner · Walnut Creek, CANPI 1588716971

Payments from drug & device makers

$9,359in general payments, 2019–2025

Across 396 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$818
  • Pfizer$724
  • Daiichi Sankyo Inc.$565
  • Merck$527
  • Amgen$519
  • Bristol Myers Squibb$439
  • plus $6K from 49 others

What the payments were for

  • Consulting fees$190%
  • Food & beverage$9,04297%
  • Education$2993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,359 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$92,038
Medicare patients
346
Services billed
882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide58$1,162,891
RevlimidLenalidomide59$1,039,799
Lenalidomide73$968,153
TagrissoOsimertinib Mesylate32$597,859
CalquenceAcalabrutinib Maleate33$502,436
IbrancePalbociclib33$456,030
JakafiRuxolitinib Phosphate23$334,428
AlecensaAlectinib Hcl14$249,335
VenclextaVenetoclax40$249,204
XtandiEnzalutamide18$233,842
BrukinsaZanubrutinib11$89,762
TasignaNilotinib Hcl11$68,119
EliquisApixaban36$38,470
XareltoRivaroxaban24$22,975
Imatinib Mesylate27$12,465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$380$1,162,89158 claims
AstraZenecaTagrisso, Calquence$397$1,100,29565 claims
Bristol Myers SquibbRevlimid$439$1,039,79959 claims
PfizerIbrance, Eliquis$724$494,50069 claims
Incyte CorporationJakafi$102$334,42823 claims
Genentech USA, Inc.Alecensa$159$249,33514 claims
AbbVieVenclexta$170$249,20440 claims
Astellas Pharma US IncXtandi$266$233,84218 claims
Beigene USA, Inc.Brukinsa$21$89,76211 claims
NovartisTasigna$396$68,11911 claims
Johnson & JohnsonXarelto$818$22,97524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →